• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

    Simply Wall St·08/10/2026 12:31:48
    Listen to the news
    • Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well tolerated and associated with improvements in pain, stiffness, and function, and incorporated glucocorticoid pretreatment into its ongoing Phase 2 ASCEND study following favorable safety findings.
    • By pairing encouraging long-term clinical data with a successful transition to scalable U.S.-based manufacturing and RMAT/ATMP regulatory designations, Pacira has moved PCRX-201 closer to potential late-stage development in a disease that affects more than 15 million people in the U.S. alone.
    • We’ll now examine how the advancement of PCRX-201 into scalable Phase 2 manufacturing and enrollment could reshape Pacira BioSciences’ investment narrative.

    Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

    Pacira BioSciences Investment Narrative Recap

    To own Pacira, you have to believe its non opioid pain franchise can keep funding a gradual shift toward a more diversified, gene therapy enabled business. The new PCRX 201 data and Phase 2 progress strengthen the case for that pivot, but the key near term catalyst remains ASCEND Part A topline results by year end 2026, while the biggest risk is still execution and spend on a pipeline that may not translate into approved, revenue generating products.

    Among recent announcements, the update on 2026 guidance and Q2 results is especially relevant. Pacira modestly lowered full year revenue expectations to US$735 million to US$760 million even as it reported US$192.4 million in Q2 revenue and a swing to profitability, underscoring that pipeline investment, including PCRX 201, must be balanced against near term growth and margin pressures.

    Yet behind the promise of PCRX 201, investors should also be aware of the risk that...

    Read the full narrative on Pacira BioSciences (it's free!)

    Pacira BioSciences’ narrative projects $908.9 million revenue and $112.0 million earnings by 2028.

    Uncover how Pacira BioSciences' forecasts yield a $29.00 fair value, a 16% upside to its current price.

    Exploring Other Perspectives

    PCRX 1-Year Stock Price Chart
    PCRX 1-Year Stock Price Chart

    Some of the lowest estimate analysts were already cautious, assuming revenue of about US$865 million and earnings of roughly US$97 million by 2029, and their view of PCRX 201 and the HCAd platform as diversification upside contrasts sharply with the consensus focus on EXPAREL risk, which this new gene therapy update could cause both camps to reassess.

    Explore 3 other fair value estimates on Pacira BioSciences - why the stock might be a potential multi-bagger!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready To Venture Into Other Investment Styles?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.